Introduction
Angiogenesis plays a critical role in the growth of solid tumors by facilitating delivery of nutrients to and removal of waste products from the tumor bed. [1] [2] [3] Angiogenic molecules and neovascular response may also contribute to the pathobiology of hematologic malignancies, such as leukemia. [4] [5] [6] [7] Vascular endothelial growth factor-A (VEGF-A), a member of the VEGF family of angiogenic factors (VEGF-A, VEGF-B, VEGF-C, VEGF-D), is the principal growth and survival factor for endothelial cells. Expression of VEGF-A is upregulated in tumor tissue and overexpression of VEGF-A or exogenously administered VEGF-A promotes tumor growth and metastasis. [8] [9] [10] The trophic effects of VEGFs are mediated through three receptor tyrosine kinases (RTK): VEGFR-1/Flt-1, VEGFR-2/KDR/Flk-1 and VEGFR-3/Flt-4. The VEGFR-2 is critical for transmission of cellular signals promoting proliferation and differentiation of endothelial cells, and mice deficient in VEGFR-2 have defects in vasculogenesis, angiogenesis and hematopoiesis. 11, 12 Bone marrow specimens from patients with acute leukemia or myelodysplastic syndromes (MDSs) display increased cellular expression of VEGF-A, VEGFR-1 and VEGFR-2 by myelomonocytic precursors, associated with increased medullary neovascular density and bone marrow blast percentage. [4] [5] [6] 13, 14 Therefore, leukemic blasts may promote their own development via both paracrine and autocrine interactions. [15] [16] [17] [18] This hypothesis is supported by reports that (1) increased plasma concentration of VEGF-A at diagnosis is associated with decreased complete remission (CR) and survival in patients with untreated acute myeloid leukemia (AML) and MDS and (2) bone marrow cellular expression of VEGFR-2 is restored to normal in patients with CR after chemotherapy. 7, 19 Finally, in vitro neutralization of VEGF-A suppresses leukemia colony-forming capacity in MDS and AML. 16 Thus, the VEGF/VEGFR-2 signaling pathway has emerged as a rational therapeutic target for the treatment of AML and MDS.
PTK787/ZK 222584 (PTK/ZK) is a potent and relatively selective inhibitor of all VEGF RTK, with slightly greater activity against VEGFR-2. This inhibitor also inhibits the platelet-derived growth factor (PDGF) receptor tyrosine kinase, c-kit protein tyrosine kinase and c-fms. 20, 21 There is no known effect against other tyrosine or serine/threonine kinases and there are no cytotoxic or antiproliferative effects on cells without VEGF-R at concentrations up to 10 mM. PTK/ZK inhibits VEGF-dependent endothelial cell proliferation in vitro and in animal models and inhibits growth of subcutaneously implanted human tumor xenografts in immunodeficient nude mice, corresponding to a reduction in tumor microvessels. Also, PTK/ZK inhibits growth of primary tumors and metastases in animal models. 20, 21 Acute myeloid leukemia remains a devastating disease with few substantial improvements in therapy. Cytotoxic chemotherapy with cytosine arabinoside and an anthracycline is the cornerstone of treatment, although in many patients, particularly those with poor-risk cytogenetics, advanced age or refractory disease, there is little expectation for long-term control. For patients with a short (o12 months) or absent remission after induction, chemotherapy may produce short-term responses, but survival 41 year is rare. Allogeneic stem cell transplantation can result in 20-40% long-term survival, but few patients with AML are eligible for the procedure. Advanced MDS also carries a poor prognosis, with median survival approximately 8-13 months. We hypothesized that PTK/ZK could exert a 'twopronged' attack in these diseases by inhibiting proliferation of leukemic cells and their surrounding endothelium via inhibition of VEGFR-2 and initiated a phase 1 study.
Materials and methods
This was an open-label, multi-center study to assess the safety, tolerability, biologic activity and pharmacologic profile of PTK/ZK administered orally, twice daily, on a continuous dosing schedule in patients with primary refractory or relapsed AML (Arm 1) and secondary AML, poor-prognosis de novo AML or advanced MDS (Arm 2). All study patients gave witnessed written consent for study participation and the Institutional Review Boards at all participating institutions approved the protocol.
Patient selection
Patients 18 years of age or older were enrolled into two groups: Patients were required to have baseline serum bilirubin p1.5 Â upper limit of normal (ULN), serum creatinine p1.5 Â ULN, 24-h creatinine clearance X50 ml/min, total urinary protein over 24 h p500 mg, liver transaminases p3 Â ULN and Karnofsky performance status X60%. Hydroxyurea was permitted for up to 72 h before study drug. Patients with central nervous system leukemia, concurrent severe medical disease, acute or chronic liver disease or severe impairment of gastrointestinal absorption were excluded. Patients suitable for stem cell transplantation were also excluded. Finally, patients who had received other investigational therapies within 4 weeks of study entry, or other chemotherapy, biologic, hormonal or immunotherapy less than 2 weeks before study entry were excluded.
Treatment protocol and study design PTK/ZK was supplied by Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA, as a 250 mg tablet to be swallowed whole with water. The study was designed as an open-label, three-center, standard phase I dose escalation trial with cohorts of 3-6 patients. Three patients were enrolled per dose cohort on each arm and an additional three patients were enrolled at the same dose level in the event that a dose-limiting toxicity (DLT) was observed. The primary objectives were to determine the maximum tolerated dose (MTD) and DLT, defined as: (1) nonhematologic common toxicity criteria (CTC) grade 3 or 4 drug-related adverse events, excluding alopecia and CTC grade 3 or 4 elevation in alkaline phosphatase (CTC grade 3 nausea and CTC grade 3 or 4 emesis were considered dose-limiting if they persisted despite standard antiemetic therapy and were related to PTK/ZK); (2) Xgrade 2 proteinuria or hematuria; (3) serum creatinine X2 Â ULN; (4) persistent grade 4 hematologic toxicity 428 days and not related to underlying disease; (5) CTC grade 3 ataxia or dizziness (or similar symptoms) lasting 410 days with continued dosing of PTK/ZK, CTC grade 4 ataxia or dizziness, or any grade of ataxia or dizziness or similar symptoms leading to discontinuation of PTK/ZK. Each arm of the trial enrolled separately and in parallel, with a starting dose of 500 mg twice daily (b.i.d.); the dose escalation schedule was based on preliminary pharmacokinetic (PK) data available from other ongoing clinical trials of PTK/ZK. PTK/ZK was given at doses of 500, 750 and 1000 mg b.i.d. One within-patient dose escalation was permitted from day 14 onward if disease progression was documented. The first three patients at each dose level were treated and observed for 28 days following the first dose of PTK/ZK with completion of all required safety evaluations before the next cohort of patients was treated. Patients continued treatment with study drug until unacceptable toxicity or disease progression was observed.
Patients enrolled onto Arm 2 were able to receive PTK/ZK monotherapy followed by combination therapy with standard induction doses of cytosine arabinoside (100 mg/m 2 /day for 7 days) and daunorubicin (45-60 mg/m 2 /day for 3 days) if monotherapy was ineffective. PTK/ZK was given at 500 mg b.i.d. starting on day 2 of chemotherapy; there was no dose escalation. Initially, patients were required to receive 28 days of PTK/ZK monotherapy before starting chemotherapy. Subsequently, the investigators determined that certain patients, especially those with rapidly escalating leukocytosis, would benefit from up-front combination of chemotherapy with PTK/ ZK. After safety data were available, exceptions were granted on a case-by-case basis to allow Arm 2 patients to receive up-front combination treatment. Thus, Arm 2 was divided into arms 2M (patients treated with monotherapy) and 2C (patients treated with PTK/ZK and chemotherapy).
Pharmacokinetic data from previous clinical trials of PTK/ZK demonstrate rapid absorption after oral administration, with a time to reach peak concentration of 1-2.5 h and an average terminal half-life of 4.5 h. 22 The drug is a substrate for and inhibitor of several cytochrome P450 enzymes, including predominantly CYP3A4, and also CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1. Therefore, concomitant therapy with agents that induce or inhibit these enzymes was avoided and treatment with coumadin and consumption of grapefruit juice were prohibited. Patients received standard supportive care as per the institutional guidelines, including antibiotics, antiemetics, antidiarrheals, analgesics and transfusions of blood and blood products. Colony-stimulating factors were not used.
Patient evaluation
History and physical examination were performed within 3 days of study entry and at the beginning of each treatment cycle. The following baseline laboratory parameters were obtained: complete blood count with differential, biochemistry panel, coagulation profile, urinalysis, chest X-ray and electrocardiogram. Bone marrow aspirate and biopsy with histochemical, cytogenetic and immunophenotypic analysis were obtained at baseline and at the end of each treatment cycle or more frequently if clinically indicated. A pregnancy test was required for women of childbearing potential. Also, because toxicology studies of PTK/ZK in rats demonstrated diffuse intestinal mucosal hyperplasia, a barium swallow study of the upper gastrointestinal tract was required at baseline and at the end of every third cycle. Of note, this finding was not observed in subsequent toxicology studies in dogs. Finally, 24-h urine collection for total protein and creatinine clearance were measured at baseline and, depending on the results, at the beginning of each subsequent treatment cycle because preclinical toxicology studies demonstrated renal insufficiency and uremia in some animals treated with high doses of PTK/ZK. Physical examination, adverse event evaluation and hematologic and biochemical panels were repeated at weekly intervals and as clinically indicated. All patients who received any PTK/ZK were considered evaluable for toxicity, which was assessed according to the National Cancer Institute CTC Version 2.0. Response criteria were based on guidelines established by the International Working Group. 23 Pharmacokinetic sampling of PTK/ZK was performed on both arms of the trial. Blood samples were collected in heparinized tubes at pre-dose and 1, 2, 4, 8, 9, 10, 12 and 24 h post-dose on days 1 and 14. After centrifugation, plasma was extracted and stored at À801C until analysis by a validated HPLC/UV method as previously published. 22 Pharmacokinetic assessments of daunorubicin and cytosine arabinoside were also obtained from patients treated on Arm 2.
Data were collected on demographic and baseline characteristics, measurements of efficacy and safety and pharmacokinetics.
Results

Patient characteristics
withdrew consent from the study. Arm 1 included 10 refractory and eight relapsed AML patients. Arm 2 had 20 patients with advanced MDS (mean age 70 years) and 25 patients with AML (mean age 70 years). Of the AML patients, seven had secondary disease, including two patients o 60 years (ages 51 and 55). On Arm 2, seven patients were treated initially with monotherapy and subsequently received combination therapy with PTK/ZK and chemotherapy, and 10 patients were treated with the combination up-front. Baseline patient characteristics are summarized in Table 1 .
Safety
Adverse events on Arms 1 or 2 which were suspected to be related to study drug and occurred in 410% of patients were nausea, emesis, dizziness, generalized weakness, fatigue, anorexia, diarrhea, lethargy, hypertension and pruritus. They were mostly grade 1 and 2 by CTC criteria and were reversible upon discontinuation of PTK/ZK. Grade 3 hypertension was reported and was reversible with antihypertensive medication in all except one patient. Dose-limiting toxicities in Arm 1 were lethargy and hypertension, seen at 1000 mg b.i.d. On Arm 2M, DLTs were nausea, emesis and anorexia, also at 1000 mg b.i.d. Therefore, the MTD for PTK/ZK monotherapy was 750 mg b.i.d.
As expected for AML patients treated with chemotherapy, almost all patients experienced grade 3 or 4 adverse events. Those taking place in 410% of patients included: febrile neutropenia (77%), hypertension (35%), sepsis (24%), bacteremia (30%), dyspnea (18%), catheter complications (12%), hyperbilirubinemia (12%), hypokalemia (12%), hyperglycemia (12%), hypophosphatemia (12%), respiratory failure (12%) and tachycardia (12%). In general, the addition of PTK/ZK to daunorubicin and cytosine arabinoside did not appear to exacerbate expected hematologic and non-hematologic chemotherapyrelated toxicities, and there was no delay in restoration of normal hematopoiesis. Specific toxicities on Arm 2C which were suspected to be drug-related included nausea, anorexia, thrombocytopenia, urinary frequency, atrial fibrillation, myocardial infarction and pulmonary embolus, all of which are detailed below.
In Arm 2C, one DLT (hyperbilirubinemia) was identified in the first six evaluable patients. The group was expanded to include seven additional patients while PK data were evaluated. In the expansion group, one patient experienced grade 3 nausea and anorexia. One patient was removed from study after the 28-day DLT evaluation period owing to suspected drug-related thrombocytopenia. Another patient, also outside the DLT evaluation period, was removed from study owing to suspected drugrelated urinary frequency. One patient treated with combination therapy experienced atrial fibrillation complicated by a cerebrovascular accident and myocardial infarction; the patient recovered completely from these events and they were not clearly drug-related, as the patient was simultaneously being treated for sepsis. A second patient, who received combination therapy after 1 month of PTK/ZK monotherapy, had a pulmonary embolus 9 days after the combination was started; study drug was discontinued. Four patients died while on study owing to complications of leukemia.
Suspected drug-related grade 3 or 4 adverse events in PTK monotherapy were infrequent, with none at the 500 mg b.i.d. dose level. At 750 mg b.i.d. and 1000 mg b.i.d., events included nausea, emesis, hypertension, anorexia, asthenia, fatigue, lethargy, dizziness, eructation, hiccups, hyperbilirubinemia, proteinuria, pyrexia, rash, thrombocytopenia and elevated transaminases. These findings are summarized in Table 2 .
Pharmacokinetics
Pharmacokinetic analyses revealed that after an initial induction of clearance, steady state was reached by day 14. The average daily exposure on day 1 and day 14 over daily dose range of 1000-2000 mg/day is shown in Figure 1 . Average PK parameters are displayed in Table 3 .
There was no accumulation of PTK/ZK with repeat dosing. PTK/ZK exposure increased with the increase in dose on day 1, but there was no notable increase in exposure at steady state beyond the MTD of 750 mg b.i.d. PTK/ZK PK parameters in monotherapy arms 1 and 2A with b.i.d. dosing were similar to once daily dosing from previously published studies. 22 Peak levels were well above the IC 50 for VEGFR-2 (IC 50 ¼ 0.037 mM). PTK/ZK did not affect the pharmacokinetics of cytosine arabinoside, but combination therapy with PTK/ZK appeared to decrease daunorubicin clearance by approximately 36%. The pharmacokinetics of PTK/ZK were not affected by the combination (data not shown). Detailed pharmacokinetics data on daunorubicin and cytosine arabinoside will be reported separately. Table 4 .
Discussion
There is strong scientific rationale for using VEGF tyrosine kinase inhibitors to treat myeloid malignancies. This study shows that PTK/ZK is generally well tolerated in patients with AML and MDS, with a favorable safety profile. Dose-limiting toxicities were lethargy and hypertension in Arm 1 and nausea, emesis and anorexia in Arm 2M. The MTD for PTK/ZK monotherapy was 750 mg orally b.i.d., supporting the results of Thomas et al. 24 The most commonly reported drug-related adverse events on both arms were nausea, emesis, dizziness, generalized weakness, fatigue, anorexia, diarrhea, lethargy, hypertension and pruritus. These occurred in 410% of patients and were mostly grade 1 or 2 and reversible with discontinuation of study drug. Grade 3 or 4 events were infrequent and were fewer in number and milder in quality than those commonly observed with chemotherapy. Finally, the gastrointestinal and renal abnormalities noted in preclinical work using high doses of PTK/ZK were not observed.
In a recent review, Gasparini et al. describe the rationale for combining antiangiogenic agents with other anticancer therapies, including (1) antiangiogenic and cytotoxic agents work independently on different cellular targets; (2) angiogenesis inhibitors reduce interstitial pressure and favor tissue diffusion of chemotherapy; (3) anti-VEGF compounds increase vessel permeability and extravasation of cytotoxic agents and (4) combination therapy may result in reduced secretion of both soluble endothelial growth factors and soluble tumor growth factors. 25 The addition of PTK/ZK to daunorubicin and cytosine arabinoside did not exacerbate expected hematologic or nonhematologic chemotherapy-related toxicities, and there was no delay in restoration of hematopoiesis. Grade 3 non-hematologic, drug-related adverse events were infrequent in the combination therapy arm and observed primarily in patients who received PTK/ZK monotherapy first, suggesting that toxicities may have been confounded by progression of disease and/or worsening performance status in patients who waited 28 days before starting chemotherapy. Monotherapy with PTK/ZK resulted in no significant clinical efficacy in patients with relapsed, refractory or newly diagnosed poor-prognosis AML, although two patients did have prolonged stabilization of disease, suggesting some biological activity. Combining PTK/ ZK with chemotherapy was feasible, with preliminary efficacy results in a small group of patients comparable to those found with standard chemotherapy. It is not known whether any effects of PTK/ZK resulted from independent action of the drug, or from Table 2 Suspected drug-related grade 3/4 adverse events in PTK787/ZK 222584 monotherapy 24 Again, PTK/ZK exposure at steady state did not notably increase with doses above 500 mg b.i.d. The decrease in exposure between day 1 and day 14 and the plateau in systemic exposure with doses above 500 mg b.i.d. are also consistent with previously published data following once daily administration of PTK/ZK. 22 Defects in coagulation, both bleeding and thrombosis, have been concerning consequences of regimens combining antiangiogenesis agents with chemotherapy. In this trial, three thrombotic events (two in the same patient) were observed in the combination therapy arm. One patient experienced a pulmonary embolus and another had both a myocardial infarction and a cerebrovascular accident. The latter patient had concurrent atrial fibrillation, as well as clinical sepsis at the time of these events, making their attribution to therapy unclear. Clinical studies of SU5416, an oral inhibitor of VEGFR-2, showed thromboembolic events in 7% of AML patients treated with monotherapy and in 22-42% of solid tumor patients treated with chemotherapy in combination with SU5416 (Fiedler W et al., American Society of Clinical Oncology Program Proceedings 2001; 20: 288, abstract). 26 The VEGFR-2 inhibitors may cause endothelial cell injury and a prothrombotic state. In a study of refractory acute leukemia patients treated with sequential chemotherapy and the VEGF monoclonal antibody bevacizumab, Karp et al. 27 observed decreased ejection fraction and cerebrovascular bleeding as major toxicities. There was no severe bleeding attributed to PTK/ZK in this trial and, although serial echocardiograms were not assessed, there was no clinical evidence of compromised cardiac function.
Many cytokines and signaling pathways may enable expansion of a leukemic clone. The lack of significant clinical efficacy in single-agent trials of small molecule inhibitors in AML supports the hypothesis that combinations of agents will be necessary for disease control. Also, in AML and MDS, which generally relapse despite therapy, post-remission strategies using well-tolerated small molecule inhibitors may be useful. A new classification of leukemia, emphasizing cytokines and receptors, may allow selection of appropriate tyrosine kinase and other inhibitors specifically tailored to the patient's leukemic cells. 
